SARA LÓPEZ TARRUELLA COBO-rekin lankidetzan egindako argitalpenak (6)

2024

  1. Correlation between breast cancer subtypes determined by immunohistochemistry and n-COUNTER PAM50 assay: a real-world study

    Breast Cancer Research and Treatment, Vol. 203, Núm. 1, pp. 163-172

  2. Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2− advanced breast cancer: a real-world evidence cohort

    Breast Cancer Research and Treatment, Vol. 206, Núm. 3, pp. 551-559

  3. Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy

    Clinical Cancer Research, Vol. 30, Núm. 10, pp. 2160-2169

2023

  1. Assessment of a Genomic Assay in Patients with ERBB2 -Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy with or Without Pertuzumab

    JAMA Oncology, Vol. 9, Núm. 6, pp. 841-846

2019

  1. Concordance of genomic variants in matched primary breast cancer, metastatic tumor, and circulating tumor DNA: The Mirror study

    JCO Precision Oncology, Vol. 3

2005

  1. Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer

    Clinical Breast Cancer, Vol. 6, Núm. 4, pp. 325-329